Iovance Biotherapeutics to Host Fourth Quarter and Full Year 2022…
SAN CARLOS, Calif., February 21, 2023 (GLOBE NEWSWIRE) — Iovance Biotherapeutics, Inc. IOVAa late-stage biotechnology company developing novel T-cell-based cancer immunotherapies will report its fourth